Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

EntreMed Opens China Office

publication date: Mar 7, 2012
EntreMed, a Washington DC area biotech, has reacquired the China rights to its leading cancer drug candidate, ENMD-2076, and the company will open a China office to direct its work necessary for SFDA approval of the molecule. In 2010, EntreMed gave Selected Value Therapeutics a 16-month option on the China rights to ENMD-2076 as part of a $5.1 million funding. Now, following a $10 million capital raise from investors with China roots and the expiration of the prior deal, EntreMed is moving ahead on its own. More details....

Stock Symbol: (NSDQ: ENMD)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital